Sanofi’s Ketek Gets December Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-day meeting expected to focus on safety issues related to the antibiotic, which has been associated with liver injury.
You may also be interested in...
Grassley Places Hold On Von Eschenbach
The FDA commissioner nominee may have to wait as the senator complains about ignored subpoenas and delayed responses by the agency to committee requests.
Grassley Places Hold On Von Eschenbach
The FDA commissioner nominee may have to wait as the senator complains about ignored subpoenas and delayed responses by the agency to committee requests.
Ketek Risk Cannot Be Distinguished From Class, FDA Says
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.